Immunoprecise Antibodies Ltd (IPA)

Currency in USD
1.810
-0.020(-1.09%)
Closed·
After Hours
1.860+0.050(+2.76%)
·
IPA Scorecard
Full Analysis
Stock generally trades with high price volatility
IPA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.7301.880
52 wk Range
0.2702.410
Key Statistics
Prev. Close
1.81
Open
1.88
Day's Range
1.73-1.88
52 wk Range
0.27-2.41
Volume
570.71K
Average Volume (3m)
2.43M
1-Year Change
122.85%
Book Value / Share
0.37
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IPA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.000
Upside
+120.99%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Immunoprecise Antibodies Ltd Company Profile

ImmunoPrecise Antibodies Ltd. operates as a AI-driven biotherapeutic research and technology company. It leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies; and support the discovery and development of therapeutic antibodies. The company’s contract research organizations services include B cell Select platforms that enable antibody screening directly from B cells, facilitating the analysis of a set of antibodies, as well as for screening compared to traditional technologies; phage display services that are based on building custom immune libraries from various species; DeepDisplay, a technology utilizing a combination of transgenic animal platforms; bispecific Abthena technology; antibody humanization services; affinity maturation services; antibody development services; protein manufacturing; and cell line development services of target proteins or antibodies. It is also involved in the development and licensing of antibody discovery platforms and related IP assets. The company was founded in 1983 and is based in Seri Kembangan, Malaysia.

Employees
92

Immunoprecise Antibodies Ltd Earnings Call Summary for Q4/2025

  • ImmunoPrecise reported record Q4 revenue of $7M, with gross margin improving to 64% from 48% YoY, despite a 14.74% stock price drop post-earnings
  • BioStrand segment grew 180% YoY, driven by increased interest in AI-driven preclinical drug development; company expects continued growth in this area
  • Company completing divestiture of Dutch subsidiary and rebranding to emphasize AI platform capabilities; anticipates revenue from oncology partnership in Q2
  • CEO Jennifer Bass highlighted positioning for 'earlier insights, stronger candidate selection, and faster decision making at scale' in drug development
  • Despite positive financials, stock fell sharply, potentially reflecting broader market concerns or undisclosed company-specific factors
Last Updated: 29/07/2025, 17:08
Read Full Transcript

Compare IPA to Peers and Sector

Metrics to compare
IPA
Peers
Sector
Relationship
P/E Ratio
−3.8x−3.5x−0.5x
PEG Ratio
−0.350.000.00
Price/Book
4.9x1.2x2.6x
Price / LTM Sales
4.7x2.5x3.3x
Upside (Analyst Target)
118.6%41.8%42.8%
Fair Value Upside
Unlock18.4%6.5%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 4.000
(+120.99% Upside)

Earnings

Latest Release
Jul 29, 2025
EPS / Forecast
-0.05 / -0.07
Revenue / Forecast
6.98M / --
EPS Revisions
Last 90 days

IPA Income Statement

People Also Watch

0.98
KLTO
-2.00%
6.945
TRON
-5.70%
33.30
BMNR
+6.97%
2.180
VOR
+3.32%
0.869
GAME
+0.58%

FAQ

What Stock Exchange Does Immunoprecise Trade On?

Immunoprecise is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Immunoprecise?

The stock symbol for Immunoprecise is "IPA."

What Is the Immunoprecise Market Cap?

As of today, Immunoprecise market cap is 83.54M.

What Is Immunoprecise's Earnings Per Share (TTM)?

The Immunoprecise EPS (TTM) is -0.91.

From a Technical Analysis Perspective, Is IPA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Immunoprecise Stock Split?

Immunoprecise has split 1 times.

How Many Employees Does Immunoprecise Have?

Immunoprecise has 92 employees.

What is the current trading status of Immunoprecise (IPA)?

As of 06 Aug 2025, Immunoprecise (IPA) is trading at a price of 1.81, with a previous close of 1.81. The stock has fluctuated within a day range of 1.73 to 1.88, while its 52-week range spans from 0.27 to 2.41.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.